Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Ortopedi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Orthopaedics (hsv//eng)

Nyckelord

Non-U.S. Gov't

Osteoporosis

Bone Density: drug effects

Biological Markers: blood

Alendronate: therapeutic use

Aged

Bone Remodeling: drug effects

Lumbar Vertebrae: drug effects

Human

Femur Neck: physiopathology

Femur Neck: drug effects

Female

Drug Synergism

Double-Blind Method

Collagen: antagonists & inhibitors

Bone Remodeling: physiology

Lumbar Vertebrae: physiopathology

Osteocalcin: antagonists & inhibitors

Middle Age

Postmenopausal: drug therapy

Postmenopausal: physiopathology

Peptides: antagonists & inhibitors

Raloxifene: therapeutic use

Selective Estrogen Receptor Modulators: therapeutic use

Support

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)